You have no items in your shopping cart.
Description
Research Area
Images & Validation
−
| Application Notes |
|---|
Key Properties
−| Source | Escherichia Coli |
|---|---|
| Biological Activity | The TNFRSF10B reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10ng/mL) but in the presence of TNFRSF10B, TRAIL-induced TNF is suppressed. |
| Purity | Greater than 95.0% as determined by SDS-PAGE. |
| Protein Sequence | ESALITQQD LAPQQRVAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH KES |
Storage & Handling
−| Storage | Stability: Lyophilized TNFRSF10B although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution TNFRSF10B should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles |
|---|---|
| Form/Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Buffer/Preservatives | Lyophilized from a 0.2µm filtered concentrated solution in PBS, pH 7.4. |
| Expiration Date | 6 months from date of receipt. |
| Disclaimer | For research use only |
Alternative Names
−Similar Products
−Human TRAIL R2/TNFRSF10B Reference Antibody (Conatumumab, RUO) [orb2978312]
ELISA, FA, FACS, In vivo
Human
Human
Monoclonal
Unconjugated
100 μg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgHuman TRAIL R2/TNFRSF10B Reference Antibody (Lexatumumab, RUO) [orb2978310]
ELISA, FA, FACS, In vivo
Human
Human
Monoclonal
Unconjugated
100 μg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgHuman TRAIL R2/TNFRSF10B Reference Antibody (Drozitumab, RUO) [orb2978311]
ELISA, FA, FACS, In vivo
Human
Human
Monoclonal
Unconjugated
100 μg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgRecombinant Mouse TRAIL R2 Protein [orb2994514]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 40.9 KDa. Observed: 50-75 KDa, reducing conditions
10 μg, 500 μg, 1 mg, 50 μgRecombinant Human TRAIL R2 Protein [orb2995140]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 15.3 KDa. Observed: 16-22 KDa, reducing conditions
10 μg, 50 μg, 500 μg, 1 mg

Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.












